Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Carlos III Health Institute | OTHER_GOV |
| University of Sao Paulo | OTHER |
| National University of Ireland, Galway, Ireland | OTHER |
| Amsterdam UMC |
Not provided
Not provided
Not provided
Not provided
This study aims to compare epidemiology, management of invasive ventilation and outcomes in critically ill patients with COVID-19 ARDS and ARDS from another pulmonary infection. The investigators will use individual patient data from four recently published large observational COVID-9 studies, including the 'Practice of VENTilation in COVID-19 patients' (PRoVENT-COVID) study, the 'Epidemiology of COVID-19 patients in the ICU' (EPICCoV) study, the 'SATI-COVID-19 - Clinical Characteristics and Outcomes of Patients With COVID-19 on Mechanical Ventilation in Argentina: a Prospective, Multicenter Cohort Study' and the CIBERESUCICOVID - Personalized Risk and Prognosis Factors and Follow-up at One Year of the Patients Hospitalized in the Spanish Intensive Care Units Infected with COVID -19' study. The investigators will use the individual patient data from ARDS patients with another pulmonary infection from the 'LUNG -SAFE - Large Observational Study to UNderstand the Global Impact of Severe Acute Respiratory FailurE' study and the 'ERICC - Epidemiology of Respiratory Insufficiency in Critical Care' study.
Early on in the pandemic, it was frequently proposed that ARDS caused by COVID-19 and ARDS caused by another cause were distinct in a number of ways. COVID-19 related ARDS phenotypes have been suggested, based on differences in respiratory system compliance (Crs) and the severity of the hypoxemia. Other reports have even suggested that lung-protective ventilation strategies for patients with ARDS caused by COVID-19 should differ from those used before the pandemic.
The use of low tidal volumes (VT) and prone positioning, which have been shown to be useful in reducing death in patients with ARDS prior to the pandemic, were also shown to be effective in patients with COVID-19 related ARDS, according to several reports. In the discussion of how to ventilate patients with COVID-19 related ARDS, the disagreement over other ventilatory settings, such as the best positive end-expiratory pressure (PEEP) and the use of recruitment manoeuvres, remains remarkably lively.
To compare epidemiology, management of invasive ventilation and outcomes in critically ill patients with COVID-19 ARDS and ARDS from another pulmonary infection, the investigators will use individual patient data from PRoVENT-COVID, EPICCoV, SATI-COVID-19, CIBERESUCICOVID, LUNG-SAFE and ERICC.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Non-COVID-19 ARDS | To be included in this analysis the cause for ARDS was a pulmonary infection other than COVID-19 and meeting all aspects of the Berlin definition. | ||
| COVID-19 ARDS | To be included in this analysis the cause for ARDS was COVID-19 and meeting all aspects of the Berlin definition. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Characteristics of invasive ventilation | A combination of key ventilation characteristics, including tidal volume (VT); positive end-expiratory pressure (PEEP); fraction inspired oxygen (FiO2); peak pressure (Ppeak) and plateau pressure (Pplat); respiratory rate (RR); driving pressure (ΔP); respiratory system compliance (CRS) and mechanical power of ventilation (MP). | Day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Ventilator-free days | Liberated of invasive ventilation and alive | 28 days |
| Incidence of ICU mortality | Incidence of ICU mortality at day 28 and at day 90 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Adult critically ill patients receiving invasive ventilation due to ARDS caused by COVID -19 or a pulmonary infection from another origen.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David MP van Meenen, PhD | Amsterdam UMC, location AMC | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Interzonal General de Agudos'General Jose de San Martin' | La Plata | Argentina | ||||
| Hospital Sirio-Libanes |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41707405 | Derived | Dorland G, Blok SG, Swart P, van der Ven FLIM, Hollmann MW, Azevedo LC, Bellani G, Botta M, Estenssoro E, Fan E, Ferreira JC, Laffey JG, Martin-Loeches I, Motos A, Pham T, Penuelas O, Pesenti A, Pisani L, Neto AS, Schultz MJ, Torres A, Tsonas AM, Paulus F, Hemmes SNT, van Meenen DMP; ERICC-investigators; LUNG SAFE-investigators; PRoVENT-COVID-investigators; EPICCoV-investigators; CIBERESUCICOVID-investigators; SATI-COVID-19-investigators. Potentially modifiable ventilatory factors contributing to outcome in patients with pulmonary and extrapulmonary ARDS - An individual patient data analysis. J Clin Anesth. 2026 Mar;110:112120. doi: 10.1016/j.jclinane.2025.112120. Epub 2026 Feb 17. | |
| 39153979 |
Not provided
Not provided
The database will be available after publication of the main publication upon reasonable request after consent of the steering committee. Request must be accompanied by a statistical analysis plan.
One year after publication of the main publication
All requests must be accompanied by a statistical analysis plan
Not provided
Not provided
| ID | Term |
|---|---|
| D012128 | Respiratory Distress Syndrome |
| D000086382 | COVID-19 |
| D011014 | Pneumonia |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012120 | Respiration Disorders |
| D011024 | Pneumonia, Viral |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
| 90 days |
| Incidence of in-hospital mortality | Incidence of in-hospital mortality at day 28 and at day 90 | 90 days |
| ICU length of stay | ICU length of stay at day 28 and at day 90 | 90 days |
| Hospital length of stay | Hospital length of stay at day 28 and at day 90 | 90 days |
| São Paulo |
| Brazil |
| Univeristy of São Paulo | São Paulo | Brazil |
| University of Galway | Galway | Ireland |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Amsterdam | Netherlands |
| Carlos III health institute | Madrid | Spain |
| Derived |
| van der Ven FLIM, Blok SG, Azevedo LC, Bellani G, Botta M, Estenssoro E, Fan E, Ferreira JC, Laffey JG, Martin-Loeches I, Motos A, Pham T, Penuelas O, Pesenti A, Pisani L, Neto AS, Schultz MJ, Torres A, Tsonas AM, Paulus F, van Meenen DMP; and for the ERICC-; LUNG SAFE-; PRoVENT-COVID-; EPICCoV-; CIBERESUCICOVID-; SATI-COVID-19-investigators. Epidemiology, ventilation management and outcomes of COVID-19 ARDS patients versus patients with ARDS due to pneumonia in the Pre-COVID era. Respir Res. 2024 Aug 17;25(1):312. doi: 10.1186/s12931-024-02910-2. |
| D012141 |
| Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |